|
|
|
05.05.25 - 08:06
|
TME Pharma Announces New Strategy (Business Wire)
|
|
|
Diede van den Ouden, an experienced CEO with successful background in small-cap turnarounds, to be nominated for appointment as CEO at upcoming AGM in June 2025
Operational costs to be strongly reduced through outsourced staffing model as from July 1, 2025 while maintaining the ability to advance both NOX-A12 and NOX-E36 assets
Streamlined Supervisory Board with two members stepping down at upcoming AGM
Management confident in securing non-dilutive financing to cover short-term operational needs
Support for the new strategy and CEO nomination from existing shareholders with significant shareholdings
BERLIN--(BUSINESS WIRE)--Regulatory News:
TME Pharma N.V. (Euronext Growth Paris: ALTME), a clinical-stage biotechnology company focused on developing novel therapies for treatment of cancer by targeting the tumor microenvironment (TME), announces today a strategic change to facilitate ongoing efforts to finance the next clinical trial for NOX-A12 through agreements with pharma or financial partners.
The strat...
|
|
|
25.04.25 - 18:06
|
TME Pharma Publishes 2024 Financial Results and Provides Operating Update (Business Wire)
|
|
|
Total €7.6 million raised through multiple transactions
All convertible debt instruments removed from balance sheet during 2024
Commitment to lean cost structure while focusing on completing strategic goals
Next clinical development steps for NOX-A12 validated by regulators
Pursuit of several transaction structures in parallel for the company's drug candidates
BERLIN--(BUSINESS WIRE)--Regulatory News:
TME Pharma N.V. (Euronext Growth Paris: ALTME), a clinical-stage biotechnology company focused on developing novel therapies for treatment of cancer by targeting the tumor microenvironment (TME), announces today its financial results for the fiscal year ending December 31, 2024, and provides a business update.
The Annual Report 2024, as approved by the management and supervisory boards on April 24, 2025, is available on TME Pharma's website (www.tmepharma.com).
“TME Pharma achieved a number of significant clinical and regulatory milestones in 2024 and, as 2025 progresses, we remain committed to advanci...
|
|
|
20.01.25 - 18:03
|
TME Pharma: Half-yearly Report on the Liquidity Contract With Invest Securities (Business Wire)
|
|
|
BERLIN--(BUSINESS WIRE)--Regulatory News:
TME Pharma N.V. (Euronext Growth Paris: ALTME), a clinical-stage biotechnology company focused on developing novel therapies for treatment of cancer by targeting the tumor microenvironment (TME), announced today that pursuant to the liquidity contract entrusted to Invest Securities by TME Pharma N.V. the assets outlined below appeared on the liquidity account as of December 31, 2024.
The following assets appeared on the liquidity account as of December 31, 2024:
Number of shares: 73,874
Cash balance of the liquidity account: €9,914.70
For the period July 1, 2024 – December 31, 2024:
Total number of shares bought: 252,021
representing an amount of: €32,739.89
representing total transactions of: 367
Total number of shares sold: 241,899
representing an amount of: €33,577.49
representing total transactions of: 338
As a reminder, the following assets appeared on the liquidity account as of June 30, 2024:
Number of shares: 63,403
Cash balance of the liquidity ac...
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Börsentreff auf Facebook |
Börsentreff auf X |
Börsentreff auf Instagram
